LHC-CIDI-5 in Hong Kong
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall…
Conditions studied
Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD), Suicidal Ideation, Suicidal Plan, Suicidal Attempt, Suicidal Gesture, Nonsuicidal Self-Injury, Manic Episode, Hypomanic, Bipolar I Disorder, Bipolar Sub Disorder, Bipolar II Disorder, Generalized Anxiety Disorder (GAD), Intermittent Explosive Disorder (IED), Panic Attack, Panic Disorder, Obsessive-Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), PCL-SC PTSD, PCL-5 PTSD, Alcohol Use Disorder (AUD), Substance Use Disorder (SUD)
About this study
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders. To mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study. In a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation. This experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.
Interventions
- Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
- Diagnostic Test: LHC-CIDI-5 — The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
Primary outcomes
- Depression (Immediately following intervention or recruitment)
- Persistent Depression (Immediately following intervention or recruitment)
- Self Harm (Immediately following intervention or recruitment)
- High Mood (Immediately following intervention or recruitment)
- Worry and Anxiety (Immediately following intervention or recruitment)
- Anger Attacks (Immediately following intervention or recruitment)
- Panic Attacks (Immediately following intervention or recruitment)
- Obsessions and Compulsions (Immediately following intervention or recruitment)
Eligibility information
Study locations
- The University of Hong Kong, Hong Kong, Hong Kong
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.